Investors Can Lead Securities Fraud Lawsuit Against Unicycive Therapeutics
Rosen Law Firm urges purchasers of Unicycive Therapeutics securities between late 2025 and mid-2026 to consider leading a securities fraud lawsuit.
Press Release – New York, September 18, 2026. Law firm Rosen Law Firm today notified investors who purchased securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025, and June 29, 2026. The firm urges these investors to consider taking the lead in an ongoing securities fraud lawsuit against the company and its management.
The lawsuit alleges that Unicycive Therapeutics made misleading or false statements to investors. Specifically, the accusations focus on statements made regarding the company's business operations and its past financial condition. Such alleged misrepresentations typically lead to a decrease in the value of securities once the truth is revealed.
Rosen Law Firm specializes in securities litigation and is informing investors of their rights. Any investor who purchased UNCY stock during the specified period and suffered losses may consider discussing the matter with counsel. The law firm has set a deadline of November 11, 2026, for investors wishing to seek recovery.
Unicycive Therapeutics is expected to respond to the allegations as the litigation progresses. Investors and analysts are likely to closely monitor the proceedings and their potential impact on the company's future performance and stock price.